// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Audit of patient satisfaction with telephone reviews for inflammatory bowel disease

K. Johns - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Re-designing the IBD nurse service for children and families in Glasgow using digital working – a tertiary centre experience

V. Garrick - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Reaction rates in patients transferred from biologic to bio-similar treatment for IBD

G. Lloyd-Ford - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Limitations of a community calprotectin service and outcomes from patients tested outside of an approved pathway

L James - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

3D printed models in fistulising perianal Crohn's as a clinical tool boost education with patients and trainees

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?

T Ahmed - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

South Asian ethnicity drives differences in microbial and metabolic profiling in a newly diagnosed ulcerative colitis cohort

R Misra - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospital

A R Aspari - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Long-term outcomes in biologic-treated perianal Crohn’s fistula

S Adegbola - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

MRI fistulography

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD

S Nurbhai - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ustekinumab

Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease

M Sierra Morales - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Azathioprine dosing and metabolite measurement in paediatric inflammatory bowel disease—does one size fit all?

R Tresman - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Oraprine

Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysis

M C Choy - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Infliximab

Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results

B Bressler - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Postprandial intestinal motility and related physiology in active small-bowel Crohn’s disease

A Khalaf - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Nitroglycerin

Current smoking trends in British IBD patients in the age of e-cigarettes

K Loonat - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 years

P Jenkinson - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnet

M Aardoom - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved